What is Universal Ibogaine Inc?
, a life sciences company, develops, acquires, and operates addiction treatment clinics in Canada.
IBOGF · Verdict
Limited reward · high risk
IBOGF's standout is valuation; volatility and cash flow weigh on the picture.
Based on 88% data coverage
IBOGF · Verdict
Above average
Weak vs peers
-39% free-cash-flow margin
-88% net margin · -161% ROE
Current ratio 1.04
Earnings -19.0% CAGR
Model-based scoring. For information only — not financial advice.
, a life sciences company, develops, acquires, and operates addiction treatment clinics in Canada. The company also undertakes planned clinical trial for research into the use of ibogaine for addiction treatment. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 2.36M.
The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are high — this profile reflects meaningful downside exposure.
For informational purposes only. Not financial advice.